Clinical Study to Evaluate the Pharmacokinetics and Safety of BDP HFA Nasal Aerosol

Study Title

Clinical Study to Evaluate the Pharmacokinetics and Safety of BDP HFA Nasal Aerosol

Teva Identifier

BDP-AR-101

ClinicalTrials.gov Identifier

NCT01537692

Study Status

Completed

Trial Condition(s)

Female, Maleergic Rhinitis

Interventions

Drug: BDP HFA Nasal Aerosol | Drug: BDP HFA Inhalation Aerosol (QVAR)

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Click for participation criteria and map of study locations

Key Participation Requirements

Gender

Female, Male

Age Range

18 Years to 45 Years

Trial Duration

03/01/2009 - 06/01/2009

Phase

Phase 1

Study Type

Interventional